Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Zealand Pharma has announced that Credit Suisse Group AG now controls over 5% of Zealand's voting rights and total share capital. This acquisition aligns with Zealand's strategic focus on the development of innovative peptide-based medicines, including products like V-Go and Zegalogue. Zealand's growth trajectory includes more than 10 drug candidates advancing into clinical stages, with two already on the market. This announcement marks significant shareholder engagement and interest in Zealand's ongoing development in the biotechnology sector.
- Credit Suisse now controls over 5% of Zealand's voting rights and share capital.
- Zealand has over 10 drug candidates in clinical development.
- Two marketed products: V-Go and Zegalogue, indicating a solid product pipeline.
- None.
Company announcement – No. 71 / 2021
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:
Following the acquisition of shares in Zealand, Credit Suisse Group AG controls more than
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment severe hypoglycemia in pediatric and adult patients with diabetes aged 6 and above. To support these two marketed products Zealand built a dedicated sales force in the United States and has established itself as a fully integrated biotechnology company. In addition, license collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from Zealand-invented peptide investigational agents currently in development.
Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
Forward-Looking Statement
The above information contains forward-looking statements that provide Zealand Pharma’s expectations or forecasts of future events. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.
For further information, please contact:
| Zealand Pharma Investor Relations |
| Claudia Styslinger |
| Argot Partners |
| investors@zealandpharma.com |
| Zealand Pharma Media Relations |
| David Rosen |
| Argot Partners |
| media@zealandpharma.com |
FAQ
What recent announcement did Zealand Pharma make regarding its major shareholder?
What is the stock symbol for Zealand Pharma?
How many drug candidates does Zealand Pharma have in clinical development?
Which products has Zealand Pharma marketed?
What does Credit Suisse's stake in Zealand Pharma signify?
